<DOC>
	<DOC>NCT00298350</DOC>
	<brief_summary>The purpose of this study is to evaluate the non-inferiority of ritonavir-boosted GS-9137 relative to a ritonavir-boosted Comparator Protease Inhibitor when used as part of combination antiretroviral regimens in subjects who have failed, or are failing, protease inhibitor therapy.</brief_summary>
	<brief_title>Ritonavir-Boosted GS-9137 vs. Ritonavir-Boosted Protease Inhibitor(s) in Combination With Background ART.</brief_title>
	<detailed_description />
	<mesh_term>Immunologic Deficiency Syndromes</mesh_term>
	<mesh_term>Acquired Immunodeficiency Syndrome</mesh_term>
	<mesh_term>HIV Infections</mesh_term>
	<mesh_term>Ritonavir</mesh_term>
	<mesh_term>HIV Protease Inhibitors</mesh_term>
	<mesh_term>Protease Inhibitors</mesh_term>
	<mesh_term>Integrase Inhibitors</mesh_term>
	<criteria>HIV RNA greater than or equal to 1000 c/mL. Failed/Failing protease inhibitor based antiretroviral therapy. Stable antiretroviral therapy for greater than or equal to 30 days prior to screening. Negative Serum Pregnancy Test. GFR by Cockcroft Gault greater than or equal to 80 mL/min. AST &amp; ALT less than or equal to 2.5x ULN. Total Bilirubin less than or equal to 1.5 mg/dL. Albumin greater than 3.5 mg/dL. Prothrombin Time INR 1.01.4 Platelets greater than or equal to 50,000. Hemoglobin greater than or equal to 8.0 mg/dL. Absolute Neutrophil Count greater than or equal to 1000. New AIDS defining condition within 30 days of baseline. Prior treatment with HIV1 integrase inhibitor (except patients from 183101). Ascites or encephalopathy. Breast Feeding. Cancer Diagnosis (besides Kaposi Sarcoma or Basal Cell Carcinoma).</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>July 2008</verification_date>
	<keyword>Phase 2</keyword>
	<keyword>Phase II</keyword>
	<keyword>Randomized</keyword>
	<keyword>Controlled</keyword>
	<keyword>Comparator</keyword>
	<keyword>Partially Blind</keyword>
	<keyword>Protease Inhibitors</keyword>
	<keyword>Integrase Inhibitors</keyword>
	<keyword>Antiviral Agents</keyword>
	<keyword>Antiretroviral Agents</keyword>
	<keyword>ART</keyword>
	<keyword>ARV</keyword>
	<keyword>Highly Activity Antiretroviral Therapy</keyword>
	<keyword>HAART</keyword>
	<keyword>Treatment Experienced</keyword>
</DOC>